Uncategorized – Page 12

Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCr Bioconjugation Platform

3 weeks ago talkbio0Tagged Bioconjugation Platform, CDMO, CliCr, co-exclusive license, Cristal Therapeutics, Curapath, Drug Delivery Systems, nucleic acid delivery

Curapath; Cristal Therapeutics; CliCr Bioconjugation Platform; co-exclusive license; nucleic acid delivery; CDMO; drug delivery

Zentek Appoints Mohammed Jiwan as CEO

3 weeks ago talkbio0Tagged Appointments, CEO, commercialization, Graphene, Jiwan, Mohammed, Nanostructured Materials, Technology, ZenGUARD, Zentek

Zentek; Mohammed Jiwan; CEO appointment; ZenGUARD; nanomaterials; graphene; technology; commercialization

BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition

3 weeks ago talkbio0Tagged 67th, AI-driven, annual, Asymmetric Septal Hypertrophy, Biological Markers, BostonGene, Clinical Trials, Hematology (discipline), immune profiling, meeting, Molecular Profiling, Multiple Myeloma, Neoplasms, Precision - temporal, Stratification

BostonGene; AI-driven molecular profiling; hematology; 67th ASH Annual Meeting; immune profiling; multiple myeloma; patient stratification; clinical trials; biomarkers; precision oncology

Pharma Faces Supreme Court Deadline as IRA Price Negotiation Takes Effect

3 weeks ago talkbio0Tagged AstraZeneca, Centers for Medicare & Medicaid Services, drug price, Farxiga, Inflation, Medicare, negotiation, petition, pharmaceutical lawsuits, price controls, SCOTUS, Supreme Court

Inflation Reduction Act; SCOTUS; drug price negotiation; AstraZeneca; Medicare; pharmaceutical lawsuits; Fifth Amendment; supreme court petition; Farxiga; Centers for Medicare & Medicaid Services; price controls

Novartis Announces Plans to Lay Off 550 Workers at Swiss Factory

3 weeks ago talkbio0Tagged Investments, layoffs, Novartis, pharmaceutical manufacturing, restructuring, Schweizerhalle, Stein facility, Switzerland

Novartis; layoffs; Switzerland; Stein facility; pharmaceutical manufacturing; restructuring; Schweizerhalle investment

Novo Nordisk’s Amycretin Significantly Reduces Weight and Blood Sugar in Phase 2 Type 2 Diabetes Trial

3 weeks ago talkbio0Tagged Administration, Oral, Agonist, amycretin, Amylin Receptor Agonists, Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Glycosylated hemoglobin A, Novo Nordisk, Phase 2 clinical trial, subcutaneous administration, Weight Loss

Novo Nordisk; Amycretin; Type 2 diabetes; Weight loss; HbA1c reduction; GLP-1 agonist; Amylin receptor agonist; Phase 2 clinical trial; Subcutaneous administration; Oral administration

FDA’s Pazdur Raises Concerns Over Legality of National Priority Voucher Program Amid Internal Disagreement

3 weeks ago talkbio0Tagged CNPV, Commissioner 's National Priority Voucher, Drug Approval Process, internal disagreement, legality, Pazdur, Tidmarsh, Tumor board, United States Food and Drug Administration

FDA; Pazdur; Commissioner’s National Priority Voucher; CNPV; legality; internal disagreement; tumor board; Tidmarsh; drug approval process

FDA Approves Novartis’ Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients

3 weeks ago talkbio0Tagged Adult, Approved, gene therapy, intrathecal formulation, Itvisma, Novartis, older children, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis; FDA approval; Itvisma; Zolgensma; Spinal Muscular Atrophy (SMA); Gene Therapy; Older Children; Adults; Intrathecal Formulation

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

3 weeks ago talkbio0Tagged 2025, Asymmetric Septal Hypertrophy, CAR-T, CAR-T therapy, Eli Lilly, in vivo, Kelonia Therapeutics, Multiple Myeloma, Novartis, Phase 3 trials

ASH 2025; in vivo CAR-T; Kelonia Therapeutics; KLN-1010; multiple myeloma; Johnson & Johnson; Lilly; Novartis; CAR-T therapy; Phase 3 trials

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

3 weeks ago talkbio0Tagged AI-discovered drugs, ATR, ATR/mTOR Inhibitors, Brain Neoplasms, CNS-penetrant, dual pathway inhibition, Enki generative AI, preclinical data, PTEN-deficient tumors, Rakovina, Society for Neuro-Oncology

Rakovina Therapeutics; AI-discovered drugs; CNS-penetrant; ATR/mTOR inhibitors; preclinical data; Society for Neuro-Oncology; brain cancer; PTEN-deficient tumors; Enki generative AI; dual pathway inhibition